Tejara Capital Ltd Makes New Investment in The Chemours Company $CC

Tejara Capital Ltd purchased a new stake in shares of The Chemours Company (NYSE:CCFree Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 125,300 shares of the specialty chemicals company’s stock, valued at approximately $1,477,000. Tejara Capital Ltd owned about 0.08% of Chemours as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of the company. Y Intercept Hong Kong Ltd acquired a new position in Chemours in the 3rd quarter worth approximately $2,124,000. WINTON GROUP Ltd lifted its stake in Chemours by 103.5% during the 3rd quarter. WINTON GROUP Ltd now owns 114,100 shares of the specialty chemicals company’s stock valued at $1,807,000 after acquiring an additional 58,039 shares during the period. Hudson Bay Capital Management LP purchased a new stake in shares of Chemours in the 3rd quarter valued at $1,925,000. SG Americas Securities LLC boosted its holdings in shares of Chemours by 478.4% in the 4th quarter. SG Americas Securities LLC now owns 236,236 shares of the specialty chemicals company’s stock valued at $2,785,000 after acquiring an additional 195,393 shares during the last quarter. Finally, Wolf Hill Capital Management LP acquired a new stake in shares of Chemours in the third quarter worth $17,025,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours Stock Down 1.4%

CC opened at $24.83 on Friday. The company has a fifty day moving average of $21.85 and a two-hundred day moving average of $17.00. The stock has a market capitalization of $3.73 billion, a price-to-earnings ratio of -9.40 and a beta of 1.47. The Chemours Company has a fifty-two week low of $9.13 and a fifty-two week high of $28.67. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.87 and a current ratio of 1.82.

Chemours (NYSE:CCGet Free Report) last posted its earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.10. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The business had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period in the prior year, the company posted $0.13 EPS. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. On average, research analysts expect that The Chemours Company will post 1.31 earnings per share for the current year.

Chemours Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 16th. Stockholders of record on Sunday, May 17th will be paid a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, May 15th. Chemours’s dividend payout ratio is presently -13.26%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on CC shares. Jefferies Financial Group restated a “hold” rating and set a $17.00 target price on shares of Chemours in a research report on Monday, February 23rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Chemours in a research report on Monday, April 20th. BMO Capital Markets decreased their price objective on Chemours from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Monday, February 23rd. Morgan Stanley upped their target price on Chemours from $17.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Monday. Finally, Alembic Global Advisors reaffirmed an “overweight” rating and set a $30.00 target price on shares of Chemours in a report on Wednesday. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $23.09.

Get Our Latest Report on Chemours

About Chemours

(Free Report)

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.

Read More

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.